BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune
Go back to BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune| (NASDAQ: BYSI) | Delayed: 1.65 +0.04 (2.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.61 | 52 Week High | $ | |||
| Open | $1.58 | 52 Week Low | $ | |||
| Day High | $1.70 | P/E | N/A | |||
| Day Low | $1.58 | EPS | $ | |||
| Volume | 22,900 | |||||
